Khiron Life Sciences Corp V.KHRN.H

RE:RE:RE:Any hope here for 2020?

[Benedictus]

kyle, for someone who claims to be neither long nor short this stock, you spend an inordinate amount of time dominating this board with bearish sentiment and ridiculous ever-changing target lows for your entry (although since now you claim khiron reminds you of wework, i assume you are no longer planning to buy the stock at all). Of course the preponderance of participants on this board are on the long side (that's how these stock boards work) and to assume we're all mindless chearleaders or company employees just shows you've read up on the bashers 101 handbook on how to attempt to claim some kind of authority position on the board by apparently quoting a few snippets from an old accounting book you perused at the local library. 

care to elaborate on your vertical saturation comment? which companies are you referring to specifically in Columbia or S America in general, that are vertically integrated, low cost producers with the licenses that khrn has procured? This market downturn has provided one helluva capital crunch for the majority of mj companies, which has actually widened their moat offering khrn an even further lead as they begin proving out their clinical model in 2020. My guess is you'll ignore these questions because you're posts show a complete lack of true dd on this company and the Lat Am mj sector. 

From a valuation standpoint there's no doubt 100M mkt cap is steep based on current sales and burn rate. Based on how so many stocks have collapsed in this sector, khiron's cash horde has kept the sp from collapsing toward .30 - .50 imo (props to Chris for the timing on that last placement). The big question is how does the sales ramp look beginning around Q2 2020 and going forward. I've never said this was a slam dunk but the clinical model strategy and the team at khiron have set this company up to be a potential leader in Lat Am. Prove out the clinical model in Columbia and then bring it online in Brazil, Mexico, etc. The kuida line will take a good deal of time to get sales traction imo. If the clinical model proves slower to gain sales traction then the cash burn will certainly be the achilles heal by late 2020, so these guys have about 5 quarters to prove to the market that what they've built thus far is going to create meaningful value for customers and shareholders. All imo.